绥美凯对艾滋病有多大疗效呢？

It has strong competitiveness in the market: on the one hand, it combines several anti-HIV drugs with different mechanisms to achieve the effect of joint treatment; on the other hand, it is convenient to take, which greatly increases the patient's compliance with taking the drug, makes it easier to be accepted by the patient, and reduces the impact of the patient's inability to take the dose on time. Today we will find out how effective Suimeikai is for AIDS? 

Suimeikai is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV). HIV-infected patients, regardless of race, should be screened for the HLA-B*5701 allele before starting treatment with abacavir-containing products. If the patient is known to carry the RLA-B*5701 allele, he should not take products containing abacavir.

Judging from a large number of clinical trial data, DTG has a low discontinuation rate due to adverse drug reactions (ADR) or virological failure, which are 5.8% and 0.5% respectively. The ADR drops significantly after one year of taking the drug. The most common adverse reactions are gastrointestinal dysfunction, mental disorders and neurological disorders, but the adverse reaction rates are less than 1.5%. From the comparison with patients who failed the first-line regimen of RAL (Ascent) and EVG (Evitegravir), the other two integrase inhibitors, the number of drug-resistant mutations in Trimeq is significantly less than that of the other two drugs, making it less likely to develop drug resistance. 

Suimeikai has been approved in more than 100 countries and recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment drug for newly treated AIDS patients. Dr. Wim Swyzen, MD, head of medical affairs and vice president of GSK China/Hong Kong, said, "Through effective HIV drug treatment, the life spans of HIV patients and healthy people are getting closer and closer. Drug compliance and convenience of medication play an increasingly important role in further improving the quality of life of patients. Currently, there is no drug that can be taken once a day, one tablet at a time. The approval of Suimeikan fills this gap and meets the urgent need for convenient medication use by doctors and patients."

In 2018, GSK announced the launch of integrase DTG (Trivic) in China. Trivic has the advantages of small drug dosage, resistance to drug resistance, and low probability of drug side effects. It can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and effectively improving patients' quality of life and work.

The above is the content of the efficacy, I hope it can help you!